LetterBlood cancer journalPublished
Final analysis results from DREAMM-3, a phase 3 study of belantamab mafodotin versus pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma
Regional connection
Verified An author affiliation on the Europe PMC record names GSK. Affiliation source
- Institution
- GSK
- County
- Montgomery County
Publication record
- Type
- Letter
- Venue
- Blood cancer journal
- Published
- Topic
- Clinical care
- PubMed ID
- 42892628
- PubMed Central ID
- PMC13676618
- Open access
- Yes, open
- Added to directory
- Source checked